Zomedica (Zomedica) Change In Receivables : $-0.81 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Zomedica Change In Receivables?

Zomedica's change in receivables for the quarter that ended in Mar. 2024 was $-0.13 Mil. It means Zomedica's Accounts Receivable increased by $0.13 Mil from Dec. 2023 to Mar. 2024 .

Zomedica's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.27 Mil. It means Zomedica's Accounts Receivable increased by $0.27 Mil from Dec. 2022 to Dec. 2023 .

Zomedica's Accounts Receivable for the quarter that ended in Mar. 2024 was $1.65 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zomedica's Days Sales Outstanding for the three months ended in Mar. 2024 was 24.03.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zomedica's liquidation value for the three months ended in Mar. 2024 was $74.92 Mil.

Zomedica Change In Receivables Historical Data

The historical data trend for Zomedica's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zomedica Change In Receivables Chart

Zomedica Annual Data

Trend

Feb14

Feb15

Feb16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.01

-0.08

-0.21

-0.62

-0.27

Zomedica Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.41	-0.45	-0.51	0.28	-0.13

Zomedica Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81 Mil.

Zomedica (AMEX:ZOM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zomedica's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.649	/	6.262	*	91
=	24.03

2. In Ben Graham's calculation of liquidation value, Zomedica's accounts receivable are only considered to be worth 75% of book value:

Zomedica's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	82.962	-	11.806	+	0.75 * 1.649	+	0.5 * 5.062
=	74.92

Zomedica Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zomedica's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zomedica (Zomedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Phoenix Drive, Suite 125, Ann Arbor, MI, USA, 48108

Website

https://www.zomedica.com

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.

Executives

Johnny D Powers	director	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Heaton Larry C Ii	officer: President	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Russell Kevin Klass	officer: Vice President of Sales	C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Peter Donato	officer: Chief Financial Officer	9172 ETON AVENUE, CHATSWORTH CA 91311
Pamela Nichols	director	14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262
Karen Dehaan-fullerton	officer: Chief Counsel and Secretary	C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Anthony K Blair	officer: Chief Operating Officer	NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017
Adrian Lock	officer: VP and General Manager	C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Sean Whelan	director	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Robert Cohen	officer: Interim CEO	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Ann Cotter	officer: Chief Financial Officer & Sec.	C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Stephanie Morley	officer: COO & VP of Product Dev	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Christopher Ross Macleod	director	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Christopher Wolfenberg	director	C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Gerald Jr Solensky	director, 10 percent owner, officer: President and CEO	C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108